TRDA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Entrada Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 6.79 USD
16.1% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -30.6% below the Trend Line and sits at 16.1% of its 52-week range. The latest completed week returned 16.1%, after a -12.0% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 55/100 conviction, while the latest news-sentiment score is 49/100. Near-term considerations: earnings are due in 3d.

Setup score 27 out of 100
Latest Close 6.79 USD 31 Jul 2026
1W Return 16.1% latest completed week
4W Return -12.0% short-term follow-through
12W Return -0.7% quarterly tape
Trend Breadth 46.2% 24 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 16.1% Latest completed week; four-week move -12.0%. Indicator stack 25/36 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 55/100 conviction; expected move 21.9%. News sentiment 49/100 55 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -30.6% below the Trend Line and sits at 16.1% of its 52-week range. The latest completed week returned 16.1%, after a -12.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0712-week average 0.42

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -12.0% over four weeks, -0.7% over 12 weeks, and 17.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W16.1%
4W-12.0%
12W-0.7%
26W-40.6%
52W17.1%
Active trend streak0 weeks
Active weeks in one year24
Trend breadth46.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.84Latest activity-pressure read.
Pressure change19.6%Four-week change in activity pressure.
Leadership-29.87Latest relative-leadership reading.
RS change-25.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength8/100Blend of value, momentum, and quality. Underlying universe rank 93; rank 1 is best.
Value33/100Relative valuation strength. Underlying universe rank 68; rank 1 is best.
Quality2/100Profitability and accounting quality. Underlying universe rank 99; rank 1 is best.
Momentum26/100Medium-term price momentum. Underlying universe rank 75; rank 1 is best.
Growth10/100Revenue and earnings growth. Underlying universe rank 91; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
39.6x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-65.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-598.0%
Gross profit retained from each unit of revenue.
Operating margin
-2878.3%
Operating profit retained from revenue.
Free-cash-flow margin
-2283.1%
Free cash flow generated from revenue.
Return on invested capital
-50.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-96.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

TRDA shows volatility options pressure with a 55/100 conviction score, put-call volume ratio of 5.00, expected move of 21.9%, and Sharemaestro trend signal inactive.

Conviction55/100
Expected move21.9%
Put/call volume5.00
Pressure-57
Speculation6
Volatility96
Trend agreement79
Open options detail
Insider activity8 / 3

8 acquisitions and 3 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment49/100

Weighted news tone is neutral across 55 relevant articles.

10 positive · 35 neutral · 10 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move21.9%Nearest-chain priced movement where available.
52-week drawdown-58.7%Distance below the 52-week high.
13-week volatility16.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+16.1%Week of 31 Jul.
Worst week-52.8%Week of 8 May.
Latest week+16.1%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains7
Flat weeks0
Modest losses2
Sharp losses8
Recent vol16.6%13-week weekly-return volatility.
Base vol11.2%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew6.8% / -8.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape29/100

Trend, activity pressure, participation, and risk combine to a 29/100 tape read.

 Indicator analysis10/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.07; No reversal markers Factors15/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 56; Small Cap Core rank 72 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options59/100

TRDA shows volatility options pressure with a 55/100 conviction score, put-call volume ratio of 5.00, expected move of 21.9%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 21.9% Sentiment49/100

Weighted news tone is neutral across 55 relevant articles.

Form 144 ENTRADA THERAPEUTICS For: 30 July By Investing.com Insiders8 / 3

8 acquisitions and 3 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20266.79 USD16.1%9.79 USD12.10 USD-0.84-29.872.3MOff
24 Jul 20265.85 USD-15.1%9.89 USD12.15 USD-0.92-39.302.6MOff
17 Jul 20266.89 USD-0.4%10.05 USD12.22 USD-0.86-29.941.9MOff
10 Jul 20266.92 USD-10.4%10.18 USD12.29 USD-0.94-32.682.2MOff
3 Jul 20267.72 USD-0.3%10.32 USD12.35 USD-1.04-23.781.2MOff
26 Jun 20267.74 USD9.2%10.41 USD12.41 USD-1.16-23.152.4MOff
19 Jun 20267.09 USD9.8%10.49 USD12.46 USD-1.30-32.93907.3KOff
12 Jun 20266.46 USD1.4%10.59 USD12.51 USD-1.31-37.591.2MOff
5 Jun 20266.37 USD-9.9%10.67 USD12.56 USD-1.26-37.501.3MOff
29 May 20267.07 USD7.8%10.69 USD12.62 USD-1.20-34.341.5MOff
22 May 20266.56 USD2.8%10.68 USD12.65 USD-0.61-37.742.0MOff
15 May 20266.38 USD-6.7%10.69 USD12.68 USD-0.32-39.163.8MOff
8 May 20266.84 USD-52.8%10.67 USD12.72 USD0.10-35.536.6MOn
1 May 202614.50 USD14.8%10.65 USD12.76 USD0.4942.781.4MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.